AURORA, ON--(Marketwired - Dec 16, 2015) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General Meeting (the "Meeting") was held today as scheduled. 

Shareholders represented in person and by proxy at the Meeting elected Messrs. Yvon Bastien, Sylwester Cacek, Gary Littlejohn, Slawomir Majewski, Marek Orlowski and Sven Rohmann as directors of the Company for the ensuing year or until such time that their respective successors are elected or appointed or they otherwise cease to hold office. Based on proxies received prior to the meeting, more than 98% of the shares represented by proxy at the Meeting were voted "for" the election of each of these directors.

In addition, BDO Canada LLP were appointed as auditors.

At a board meeting held after the Meeting, Mr. Yvon Bastien was appointed Chairman of the Board, Mr. Gary Littlejohn was appointed as Interim Chief Executive Officer, Mr. Heman Chao was appointed Chief Scientific Officer and Mr. Frank Michalargias was appointed as Chief Financial Officer.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".